申请人:Fenton Garry
公开号:US20060084809A1
公开(公告)日:2006-04-20
This invention is directed to a [di(ether or thioether)heteroaryl or fluoro substituted aryl] compound or an N-oxide thereof or a pharmaceutically acceptable salt thereof, which is useful for inhibiting the production or physiological effects of TNF in the treatment of a patient suffering from a disease state associated with a physiologically detrimental excess of tumor necrosis factor (TNF). Compounds within the scope of the present invention also inhibit cyclic AMP phosphodiesterase, and are useful in treating a disease state associated with pathological conditions that are modulated by inhibiting cyclic AMP phosphodiesterase, such disease states including inflammatory and autoimmune diseases, in particular type IV cyclic AMP phosphodiesterase. The present invention is therefore directed to their pharmacological use for inhibiting TNF and/or cyclic AMP phosphodiesterase, pharmacological compositions comprising the compounds and methods for their preparation.
本发明涉及[含有(di(醚或硫醚)杂环或氟代芳基)化合物]或其N-氧化物或其药学上可接受的盐,该化合物在治疗患有与肿瘤坏死因子(TNF)生产或生理作用过量有害相关的疾病状态的患者中有用,能够抑制TNF的产生或生理作用。本发明范围内的化合物还抑制环磷酸腺苷磷酸二酯酶,并且在治疗与抑制环磷酸腺苷磷酸二酯酶相关的病理条件的疾病状态中有用,这些疾病状态包括炎症和自身免疫性疾病,特别是第四型环磷酸腺苷磷酸二酯酶。因此,本发明涉及它们在抑制TNF和/或环磷酸腺苷磷酸二酯酶方面的药理学用途,包括含有这些化合物的药理学组合物以及它们的制备方法。